Major histocompatibility complex (MHC) class I and II peptide-binding grooves (MHC I/II peptide-binding grooves)

The Major histocompatibility complex (MHC) class I and II peptide-binding grooves are specialized structural domains on the surface of antigen-presenting cells and most nucleated cells. These grooves function by capturing and displaying short peptide fragments derived from either intracellular (MHC I) or extracellular (MHC II) proteins to T-cell receptors (TCRs), a process essential for initiating adaptive immune responses (StatPearls, 2023). MHC class I grooves are formed by alpha-1 and alpha-2 domains and typically bind peptides of 8-10 amino acids, whereas MHC class II grooves are formed by alpha-1 and beta-1 domains and accommodate longer peptides (Janeway's Immunobiology, 2017). In disease states, these grooves may present self-antigens leading to autoimmunity or fail to present pathogen/tumor antigens, allowing for immune escape (Nature Reviews Immunology, 2018). Therapeutic targeting of the MHC groove includes the use of peptide-based vaccines to stimulate specific T-cell responses and drugs like Glatiramer acetate, which competitively binds to MHC class II grooves to modulate the immune response in multiple sclerosis (PubMed, 2021). Additionally, certain drugs like Abacavir can bind within the groove, altering the presented peptide repertoire and triggering severe hypersensitivity reactions (Nature, 2012). Understanding the polymorphic nature of these grooves is critical for personalized medicine, particularly in organ transplantation and predicting drug-induced adverse reactions (NIH, 2022).

Other names

HLA peptide-binding cleftMHC antigen-binding pocketMHC peptide-binding siteHuman leukocyte antigen (HLA) groovesMHC binding groove

Competitive inhibition of peptide binding, alteration of the peptide repertoire presented to T-cells (neo-antigen presentation), and induction of immune tolerance or activation through T-cell receptor modulation.